Bio Matters: Family influences led EyeCRO’s executive into scientific research

Rafal Farjo, Ph.D. is chief operating officer of both EyeCRO and Charlesson, which are involved in research to advance treatments for eye disease such as age-related macular degeneration, diabetic retinopathy and ocular inflammation. Far from resisting his family’s interest in all things STEM — science, technology, engineering and math — Farjo embraced it. “I loved it, and I actually started … [Read more...]

Kala Pharmaceuticals Announces Positive Results from Phase 2 Trial of KPI-121 in Dry Eye Disease

Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, today announced positive top-line results from a Phase 2 clinical trial of KPI-121.  KPI-121 achieved statistical significance for the primary sign endpoint of bulbar conjunctival hyperemia, and promising trends were observed for key symptom … [Read more...]

Preclinical Ophthalmic Contract Research